EcoDrugPlus

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSSMAG00000011646
Gene Symbol: PIK3R1
3 Cross references
202 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSSMAG00000009411
Gene Symbol: PIK3R3
3 Cross references
206 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSSMAG00000015653
Gene Symbol: PIK3R5
1 Cross references
200 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 2 (Beta)

Ensembl ID : ENSSMAG00000005255
Gene Symbol: PIK3R2
1 Cross references
189 Possible Orthologues:

Phospholipase A2, Group Vii (Platelet-Activating Factor Acetylhydrolase, Plasma)

Ensembl ID : ENSSMAG00000004495
Gene Symbol: PLA2G7
2 Cross references
203 Possible Orthologues:

Plasminogen

Ensembl ID : ENSSMAG00000004711
Gene Symbol: PLG
1 Cross references
253 Possible Orthologues:

Plasminogen Activator, Tissue

Ensembl ID : ENSSMAG00000006680
Gene Symbol: PLAT
2 Cross references
205 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSSMAG00000002643
Gene Symbol: PDGFRB
3 Cross references
198 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 1

Ensembl ID : ENSSMAG00000013799
Gene Symbol: PARP1
3 Cross references
209 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 2

Ensembl ID : ENSSMAG00000010446
Gene Symbol: PARP2
3 Cross references
185 Possible Orthologues:

Poly (Adp-Ribose) Polymerase Family, Member 3

Ensembl ID : ENSSMAG00000000680
Gene Symbol: PARP3
3 Cross references
197 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSSMAG00000020686
Gene Symbol: KCNMA1
1 Cross references
235 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).